-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 18, China's antibody drug pioneer Sansheng Guojian announced that the company has recently completed a Series C investment in Qi Tak Pharmaceutical
.
This round of investment was led by China Life Health Fund, with the participation of Sansheng Guojian, PICC Capital Equity Investment Company, and Wuzhong Bio-Pharmaceutical Industrial Park.
Kai Tak Pharmaceutical has been focusing on the research and development of innovative bio-conjugated drugs represented by ADC drugs.
It has a core technology portfolio that is world-leading and has global patent authorization, including enzyme-catalyzed site-specific coupling technology, innovative linker technology with unique advantages, and intelligence.
Continuous coupling (iLDC) platform technology, etc.
, effectively solve the current industry pain points such as high heterogeneity of ADC drug products, narrow therapeutic window, and full of challenges in commercial production
.
At present, the pipeline of new drug research products of Qi Tak Pharmaceutical includes both a series of potential ADC varieties with known targets (best-in-class) and the first-in-class drug product with a new mechanism of action (first-in-class).
